InvestorBrandNetwork (IBN) logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

Earth Science Tech Inc.’s (ETST) Uplist to OTCQB Venture Market Continues Series of Milestones in Fiscal 2027

September 21, 2026 Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that provides investors with a trusted trading environment The uplisting is one of several milestones the company has reported during the current financial year 2027, which began on April 1, 2026 The company reported its Q1 2027 financial results, marking a 3% growth in revenue with a 57% increase in net income The company also acquired Meduvo LLC and Zoolzy and held its annual meeting of shareholders Earth Science Tech (OTCQB: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, successfully uplisted to the OTCQB Venture Market effective September 17, 2026. The listing on OTCQB, an established public market for growth-stage and entrepreneurial companies, means ETST has met rigorous financial and reporting standards, undergone a verification process, and complied with strict management certification requirements (https://ibn.


AINewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Featured in AINewsWire Editorial on AI Semiconductor Packaging and Automation

September 21, 2026Nightfood Holdings (OTCQB: NGTF), doing business as TechForce Robotics, was featured in an AINewsWire editorial examining growing demand for semiconductor packaging, wafer inspection and automation as artificial intelligence drives increasingly complex chip production. The editorial highlights Nightfood’s formation of TechForce Advanced Manufacturing Inc.


NetworkNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Applies to More Than Double Sarfartoq Rare Earth District Footprint

September 21, 2026Greenland Mines (NASDAQ: GRML) announced that it has applied to the Government of Greenland for a new exploration license covering approximately 262 square kilometres immediately east of its existing Sarfartoq license. If granted, the new license would increase the company’s controlled footprint at Sarfartoq from approximately 192 square kilometres to approximately 454 square kilometres, more than doubling its position across the known rare earth and carbonatite district.


Injectable Nanodevices Exhibit Potency Against Brain Tumors

September 21, 2026A new nano-sized injectable technology developed at the MIT Media Lab has shown striking results against one of medicine’s toughest cancers. In lab tests, it wiped out just over half of the malignant cells in samples from patients whose tumors had stopped responding to standard drugs, a kill rate roughly five times higher than a common chemotherapy agent.


Trump Calls AI Fears a “Hoax”

September 21, 2026Artificial intelligence is becoming one of the biggest technology debates in the United States, but President Donald Trump is pushing back against growing concerns about its possible dangers. Trump has rejected calls for stronger government controls on AI, describing fears about the technology as a “hoax” and arguing that the United States should continue developing it rapidly.


AINewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Featured in AINewsWire Editorial Exploring Natural Hydrogen Role in AI Energy Demand

September 21, 2026This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) was featured in an AINewsWire editorial examining how rapidly growing electricity demand from artificial intelligence and data centers could create opportunities for energy development closer to power-intensive infrastructure.


PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Presents HLP003 Data From MDD Program at Psych Congress 2026

September 21, 2026This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the presentation of four posters evaluating HLP003, its investigational oral deuterated psilocin analog being developed as an adjunctive treatment for major depressive disorder (“MDD”), at Psych Congress 2026 in New Orleans.